The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: A cohort study

PLoS Medicine

Volumn 8, Issue 6, 2011, Pages

  Edmonds, Andrew ^a   Yotebieng, Marcel ^a   Lusiama, Jean ^b   Matumona, Yori ^b   Kitetele, Faustin ^b   Napravnik, Sonia ^a,c   Cole, Stephen R ^a   van Rie, Annelies ^a   Behets, Frieda ^a,c  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF KINSHASA   (Congo)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DEMOCRATIC REPUBLIC CONGO; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SURVIVAL; HEALTH CARE DELIVERY; METHODOLOGY; MORTALITY; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DELIVERY OF HEALTH CARE; DEMOCRATIC REPUBLIC OF THE CONGO; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 79959795008     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001044     Document Type: Article

References (44)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents (2009) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington (District of Columbia) Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 1 October 2010.
2. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
3. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
4. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. (2009) Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373: 1352-1363.
5. Kourtis AP, Ibegbu C, Nahmias AJ, Lee FK, Clark WS, et al. (1996) Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med 335: 1431-1436.
6. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, et al. (1997) Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 336: 1337-1342.
7. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 1236-1243.
8. Lindsey JC, Hughes MD, McKinney RE, Cowles MK, Englund JA, et al. (2000) Treatment-mediated changes in human immunodeficiency virus (HIV) type 1 RNA and CD4 cell counts as predictors of weight growth failure, cognitive decline, and survival in HIV-infected children. J Infect Dis 182: 1385-1393.
9. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group (2008) Response to combination antiretroviral therapy: variation by age. AIDS 22: 1463-1473.
10. Joint United Nations Programme on HIV/AIDS (2008) 2008 Report on the global HIV/AIDS epidemic. Geneva Joint United Nations Programme on HIV/AIDS.
11. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, et al. (2000) Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284: 190-197.
12. Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, et al. (2008) Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis 46: 507-515.
13. World Health Organization, Joint United Nations Programme on HIV/AIDS, and United Nations Children's Fund (2009) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2009. Geneva World Health Organization.
14. Beck E, Walensky R, (2008) The outcome and impact of ten years of HAART. In: Whiteside A, Ghaziani A, Zuniga JM, Bartlett JG, editors. A decade of HAART: the development and global impact of highly active antiretroviral therapy Oxford Oxford University Press pp. 45-63.
15. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
16. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, et al. (2008) Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 5: e148 doi:10.1371/journal.pmed.0050148.
17. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, et al. (2007) Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 298: 1888-1899.
18. George E, Noel F, Bois G, Cassagnol R, Estavien L, et al. (2007) Antiretroviral therapy for HIV-1-infected children in Haiti. J Infect Dis 195: 1411-1418.
19. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, et al. (2004) Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS 18: 1905-1913.
20. KIDS-ART-LINC Collaboration (2008) Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in sub-Saharan Africa. J Acquir Immune Defic Syndr 49: 523-531.
21. Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, et al. (2010) Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr 54: 524-532.
22. McConnell MS, Chasombat S, Siangphoe U, Yuktanont P, Lolekha R, et al. (2010) National program scale-up and patient outcomes in a pediatric antiretroviral treatment program, Thailand, 2000-2007. J Acquir Immune Defic Syndr 54: 423-429.
23. Sutcliffe CG, van Dijk JH, Bolton-Moore C, Cotham M, Tambatamba B, et al. (2010) Differences in presentation, treatment initiation, and response among children infected with human immunodeficiency virus in urban and rural Zambia. Pediatr Infect Dis J 29: 849-854.
24. Anaky MF, Duvignac J, Wemin L, Kouakoussui A, Karcher S, et al. (2010) Scaling up antiretroviral therapy for HIV-infected children in Cote d'Ivoire: determinants of survival and loss to programme. Bull World Health Organ 88: 490-499.
25. Leyenaar JK, Novosad PM, Ferrer KT, Thahane LK, Mohapi EQ, et al. (2010) Early clinical outcomes in children enrolled in human immunodeficiency virus infection care and treatment in Lesotho. Pediatr Infect Dis J 29: 340-345.
26. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, et al. (2009) Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 38: 1612-1621.
27. World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2006 revision. Geneva World Health Organization.
28. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: recommendations for a public health approach-2010 revision. Geneva World Health Organization.
29. National Program for the Fight against AIDS (2005) National guide for antiretroviral treatment of HIV infection. Kinshasa Democratic Republic of the Congo Ministry of Health.
30. Cole SR, Hernán MA, Margolick JB, Cohen MH, Robins JM, (2005) Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol 162: 471-478.
31. Robins JM, Hernán MA, Brumback B, (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: 550-560.
32. Fewell Z, Hernán MA, Wolfe F, Tilling K, Choi H, et al. (2004) Controlling for time-dependent confounding using marginal structural models. Stata J 4: 402-420.
33. Hernán MA, Brumback B, Robins JM, (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: 561-570.
34. Hernán MA, McAdams M, McGrath N, Lanoy E, Costagliola D, (2009) Observation plans in longitudinal studies with time-varying treatments. Stat Methods Med Res 18: 27-52.
35. Westreich D, Cole SR, Tien PC, Chmiel JS, Kingsley L, et al. (2010) Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol 171: 691-700.
36. Greenland S, Pearl J, Robins JM, (1999) Causal diagrams for epidemiologic research. Epidemiology 10: 37-48.
37. Coghlan B, Brennan RJ, Ngoy P, Dofara D, Otto B, et al. (2006) Mortality in the Democratic Republic of Congo: a nationwide survey. Lancet 367: 44-51.
38. HIV-CAUSAL Collaboration (2010) The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24: 123-137.
39. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, et al. (2008) Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 168: 86-93.
40. De Baets AJ, Ramet J, Msellati P, Lepage P, (2008) The unique features of pediatric HIV-1 in sub-Saharan Africa. Curr HIV Res 6: 351-362.
41. Raiten DJ, Grinspoon S, Arpadi S, (2005) Nutritional considerations in the use of ART in resource-limited settings. Geneva World Health Organization Department of Nutrition for Health and Development.
42. Fetzer BC, Hosseinipour MC, Kamthuzi P, Hyde L, Bramson B, et al. (2009) Predictors for mortality and loss to follow-up among children receiving anti-retroviral therapy in Lilongwe, Malawi. Trop Med Int Health 14: 862-869.
43. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, et al. (2005) Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 192: 24-29.
44. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, et al. (2001) Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15: 1951-1957.